Inhibition of lymphocyte CD3 expression by Chlamydophila pneumoniae infection

Microbial Pathogenesis

Volumn 45, Issue 4, 2008, Pages 290-296

  Yamaguchi, Hiroyuki ^a,b   Matsuo, Junji ^b   Sugimoto, Shigehiro ^a   Utsumi, Maki ^a   Yamamoto, Yoshimasa ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

CD3; Chlamydophila pneumoniae; lymphocytes; Molt 4 cells; prostaglandin E2

Indexed keywords

7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; CD3 ANTIGEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2;

ARTICLE; BACTERIAL INFECTION; CELL LYSATE; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEATING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION;

ANTIGENS, CD3; CELL LINE; CELLS, CULTURED; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DINOPROSTONE; DOWN-REGULATION; GENE EXPRESSION; HOST-PATHOGEN INTERACTIONS; HUMANS; LYMPHOCYTES;

CHLAMYDOPHILA PNEUMONIAE;

EID: 50949128614     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2008.06.005     Document Type: Article

References (41)

1. Grayston J.T. Chlamydia pneumoniae, strain TWAR. Chest 95 (1989) 664-669
2. Grayston J.T., Wang S.P., Kuo C.C., and Campbell L.A. Current knowledge on Chlamydia pneumoniae, strain TWAR, an important cause of pneumonia and other acute respiratory diseases. Eur J Clin Microbiol Infect Dis 8 (1989) 191-202
3. Kauppinen M., and Saikku P. Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Clin Infect Dis 21 Suppl. 3 (1995) S244-S252
4. Grayston J.T. Chlamydia pneumoniae and atherosclerosis. Rev Med Interne 17 Suppl. 1 (1996) S45-S47
5. Hahn D.L., Dodge R.W., and Golubjatnikov R. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 266 (1991) 225-230
6. Norton R., Schepetiuk S., and Kok T.W. Chlamydia pneumoniae pneumonia with endocarditis. Lancet 345 (1995) 1376-1377
7. Saario R., and Toivanen A. Chlamydia pneumoniae as a cause of reactive arthritis. Br J Rheumatol 32 (1993) 1112
8. Ieven M.M., and Hoymans V.Y. Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence. J Clin Microbiol 43 (2005) 19-24
9. Jonasson L., Holm J., Skalli O., Bondjers G., and Hansson G.K. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6 (1986) 131-138
10. Sullivan G.W., Sarembock I.J., and Linden J. The role of inflammation in vascular diseases. J Leukoc Biol 67 (2000) 591-602
11. Kaul R., Uphoff J., Wiedeman J., Yadlapalli S., and Wenman W.M. Detection of Chlamydia pneumoniae DNA in CD3+ lymphocytes from healthy blood donors and patients with coronary artery disease. Circulation 102 (2000) 2341-2346
12. Haranaga S., Yamaguchi H., Friedman H., Izumi S., and Yamamoto Y. Chlamydia pneumoniae infects and multiplies in lymphocytes in vitro. Infect Immun 69 (2001) 7753-7759
13. Yamaguchi H., Haranaga S., Friedman H., Moor J.A., Muffly K.E., and Yamamoto Y. A Chlamydia pneumoniae infection model using established human lymphocyte cell lines. FEMS Microbiol Lett 216 (2002) 229-234
14. Allison J.P., McIntyre B.W., and Bloch D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J Immunol 129 (1982) 2293-2300
15. Haskins K., Kubo R., White J., Pigeon M., Kappler J., and Marrack P. The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody. J Exp Med 157 (1983) 1149-1169
16. Meuer S.C., Fitzgerald K.A., Hussey R.E., Hodgdon C.J., Schlossman S.F., and Reinherz E.L. Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex. J Exp Med 157 (1983) 705-719
17. Minowada J., Onuma T., and Moore G.E. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 49 (1972) 891-895
18. Abraham R.T., and Weiss A. Jurkat T cells and development of the T-cell receptor signaling paradigm. Nat Rev Immunol 4 (2004) 301-308
19. Zhang X.M., Berland R., and Rosoff P.M. Differential regulation of accessory mitogenic signaling receptors by the T cell antigen receptor. Mol Immunol 32 (1995) 323-332
20. Berlin C., Berg E.L., Briskin M.J., Andrew D.P., Kilshaw P.J., Holzmann B., et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 74 (1993) 185-195
21. Beyers A.D., Spruyt L.L., and Williams A.F. Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5. Proc Natl Acad Sci USA 89 (1992) 2945-2949
22. Schonbeck U., Sukhora G.K., Graber P., Coulter S., and Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155 (1999) 1281-1291
23. Beloqui O., Paramo J.A., Orbe J., Benito A., Colina I., Monasterio A., et al. Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?. Eur Heart J 26 (2005) 153-158
24. Cipollone F., Fazia M., Iezzi A., Ciabattoni G., Pini B., Cuccurullo C., et al. Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler Thromb Vasc Biol 24 (2004) 1259-1265
25. Clement N., Glorian M., Raymondjean M., Andreani M., and Limon I. PGE2 amplifies the effects of IL-1beta on vascular smooth muscle cell de-differentiation: a consequence of the versatility of PGE2 receptors 3 due to the emerging expression of adenylyl cyclase 8. J Cell Physiol 208 (2006) 495-505
26. D'Acquisto F., Iuvone T., Rombola L., Sautebin L., Rosa Di, and Carnuccio R. Involvement of NF-κB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett 418 (1997) 175-178
27. Appleby S.B., Ristimaki A., Neilson K., Narko K., and Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem J 302 (1994) 723-727
28. Pistritto G., Franzese O., Pozzoli G., Mancuso C., Tringli G., Preziosi P., et al. Bacterial lipopolysaccharide increases prostaglandin production by rat astrocytes via inducible cyclooxygenase: evidence for the involvement of nuclear factor κB. Biochem Biophys Res Commun 263 (1999) 570-574
29. Bihoreau C., Heurtier A., Enjalbert A., Corvaia N., Bensussan A., Degos L., et al. Activation of the CD3/T cell receptor (TcR) complex or of protein kinase C potentiate adenylyl cyclase stimulation in a tumoral T cell line: involvement of two distinct intracellular pathways. Eur J Immunol 21 (1991) 2877-2882
30. Bismuth G., Theodorou I., Gouy H., Le Gouvello S., Bernard A., and Debre P. Cyclic AMP-mediated alteration of the CD2 activation process in human T lymphocytes. Preferential inhibition of the phosphoinositide cycle-related transduction pathway. Eur J Immunol 18 (1988) 1351-1357
31. Rincon M., Tugores A., Lopez-Rivas A., Silva A., Alonso M., De Landazuri M.O., et al. Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells. Eur J Immunol 18 (1988) 1791-1796
32. Snijdewint F.G., Kalinski P., Wierenga E.A., Bos J.D., and Kapsenberg M.L. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 150 (1993) 5321-5329
33. Cipollone F., Prontera C., Pini B., Marini M., Fazia M., De Cesare D., et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability. Circulation 104 (2001) 921-927
34. Anastassiou E.D., Paliogianni F., Balow J.P., Yamada H., and Boumpas D.T. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels. J Immunol 148 (1992) 2845-2852
35. Chen D., and Rothenberg E.V. Interleukin 2 transcription factors as molecular targets of cAMP inhibition: delayed inhibition kinetics and combinatorial transcription roles. J Exp Med 179 (1994) 931-942
36. Rodel J., Prochnau D., Prager K., Baumert J., Schmidt K.H., and Straube E. Chlamydia pneumoniae decreases smooth muscle cell proliferation through induction of prostaglandin E2 synthesis. Infect Immun 72 (2004) 4900-4904
37. Rupp J., Berger M., Reiling N., Gieffers J., Lindschau C., Haller H., et al. Cox-2 inhibition abrogates Chlamydia pneumoniae-induced PGE2 and MMP-1 expression. Biochem Biophys Res Commun 320 (2004) 738-744
38. Yoneda H., Miura K., Matsushima H., Sugi K., Murakami T., Ouchi K., et al. Aspirin inhibits Chlamydia pneumoniae-induced NF-kappa B activation, cyclo-oxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamydial growth. J Med Microbiol 52 (2003) 409-415
39. Fan P., Dong F., Huang Y., and Zhong G. Chlamydia pneumoniae secretion of a protease-like activity factor for degrading host cell transcription factors is required for major histocompatibility complex antigen expression. Infect Immun 70 (2002) 345-349
40. Roblin P.M., Dumornay W., and Hammerschlag M.R. Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. J Clin Microbiol 30 (1992) 1968-1971
41. Geng Y., Shane R.B., Berencsi K., Gonczol E., Zaki M.H., Margolis D.J., et al. Chlamydia pneumoniae inhibits apoptosis in human peripheral blood mononuclear cells through induction of IL-10. J Immunol 164 (2000) 5522-5529